Brandon J. Weichert Bücher

"When President Donald J. Trump announced the creation of America's sixth branch of the military, the United States Space Force, many in Washington scoffed, but U.S. rivals in China, Russia, Iran, and North Korea took notice. Since the end of the Cold War, these American foes have chafed under the full-spectrum dominance that the American superpower has enjoyed globally. They have identified space as a key strategic domain where they can challenge, and possibly defeat, the United States military. And, depriving the U.S. military and its economy of access to space during an international crisis could spell doom for the United States in other strategic domains (land, sea, air, and cyberspace) ... The net decade presents U.S. policymakers one last chance to preserve the superpower status that America fought two world wars and the Cold War to build. Time is not on our side. We are on notice, but we have not noticed."-- From the jacket cover

When COVID-19 emerged from Wuhan, China, the Communist Party attempted to conceal its existence for as long as possible. However, there is much more to the story than the authorities reveal. This work explores the Chinese Communist Party's long-term ambition to dominate the biotechnology industry, aiming to control the fundamental building blocks of life to enhance their political power domestically and assert global supremacy. Alarmingly, Western scientists, pharmaceutical companies, and research labs have unwittingly fueled China's rapid and perilous growth in biotech, potentially positioning China as the leading force in this sector. The Chinese leadership views biotechnology as essential to achieving their "China Dream" of becoming the world's dominant superpower by 2049. Within China's biotech landscape, disturbing practices are emerging, including cloning programs and the development of pathogens intended for "specific genetic attacks" against political adversaries. To address this escalating threat, the author advocates for the establishment of international treaties to regulate biotechnology research and development. Additionally, he urges the U.S. to restrict the transfer of advanced biotechnology knowledge and funding to China through mechanisms like the Foreign Corrupt Practices Act and CFIUS. Without a comprehensive approach to curtailing reckless biotech advancements in China, the world risks facing another, poten